Brief: Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse
27/09/2022 14:21
Sept 27 (Reuters) - Bellerophon Therapeutics Inc
BLPH.O :
* BELLEROPHON ANNOUNCES FDA ACCEPTANCE OF CHANGE TO ONGOING
PHASE
3 REBUILD STUDY OF INOPULSE® FOR TREATMENT OF FIBROTIC
INTERSTITIAL LUNG DISEASE
* BELLEROPHON THERAPEUTICS INC - ENROLLMENT NOW EXPECTED TO
CONCLUDE IN Q1 2023, WITH PIVOTAL TOP-LINE DATA READOUT
ANTICIPATED IN Q3 2023
* BELLEROPHON THERAPEUTICS INC - ENROLLMENT NOW EXPECTED TO
CONCLUDE IN Q1 2023, WITH PIVOTAL TOP-LINE DATA READOUT
ANTICIPATED IN Q3 2023
Source text for Eikon: ID:nGNX5n6Gv0
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen